Drug intelligence / Profile preview

NT-301

Development stage: Unknown
Lead developer: Nano PharmaSolutions
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Intranasal

Overview

NT-301 is a proprietary powder nasal spray formulation of apomorphine freebase developed by Nano PharmaSolutions for the treatment of "OFF" episodes in Parkinson's disease. The product utilizes the NanoTransformer® technology, a patented nanodrug manufacturing platform that enhances drug solubility and bioavailability via nano-coating of the active pharmaceutical ingredient. This technology enables rapid absorption through the nasal mucosa, achieving a Tmax of approximately 20 minutes in clinical studies. NT-301 is designed as a drug-device combination to provide a fast-acting, non-invasive alternative to subcutaneous apomorphine injections.

Other names: apomorphine nasal powdernasal apomorphine

Targets

DRD4 (Dopamine D4 Receptor)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD5 (Dopamine D5 Receptor)

Beyond the preview

Go deeper on NT-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-301.

Explore the full profile